Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Disoxaril is a synthetic small molecule antiviral agent belonging to the phenol ether class. It was developed as an inhibitor of human picornaviruses, including rhinoviruses and enteroviruses. Disoxaril acts by binding to a hydrophobic pocket within the viral VP1 capsid protein, thereby preventing the structural transitions required for viral uncoating and inhibiting viral replication. The compound has been studied primarily in experimental settings and is not approved for clinical use[1][2]. Its primary molecular target is the genome polyprotein of picornaviruses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on disoxaril.